1. Clinical & Scientific Overview
Diazepam (Oral, IV & Paediatric Rectal Protocol) (TIP-MED-000219, Reference Code [11.15]) is classified under
Neurology & Antiepileptic Medicines (Ch 11) as a Long-Acting Lipophilic Benzodiazepine (Anticonvulsant, Anxiolytic, Skeletal Muscle Relaxant).
Within the Indian regulatory and compendial framework, it is governed under Schedule H1 Prescription Drug (Mandatory Red-Bordered Rx Warning & 3-Year Register under Rule 65 of Drugs Rules 1945).
Representative Indian Market Examples (Edition 2.7 Ch 11 [11.15], p. 147): Valium, Calmpose, Placidox — Strengths & Dosage Forms: Tablet: 2 mg, 5 mg, 10 mg; Injection: 5 mg/mL (2 mL ampoule = 10 mg); Rectal Solution/Suppository: 5 mg, 10 mg.
Tablet: 2 mg, 5 mg, 10 mg; Injection: 5 mg/mL (2 mL ampoule = 10 mg); Rectal Solution/Suppository: 5 mg, 10 mg.
3. Mechanism of Action & Pharmacodynamics
Potentiates GABA-A receptor-mediated chloride influx in limbic, thalamic, hypothalamic, and spinal polysynaptic pathways; metabolised via CYP2C19/3A4 to active desmethyldiazepam (t1/2 up to 100 h).
4. Therapeutic Indications & Evidence-Supported Uses
- Status epilepticus and febrile convulsions (IV or rectal)
- acute alcohol withdrawal syndrome
- severe acute muscle spasm
- tetanus spasms
- acute procedural anxiety
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Adult: Status Epilepticus: 10-20 mg IV slowly (max rate 5 mg/min) or 10-20 mg PR. Muscle Spasm / Anxiety: 2-10 mg PO BD/TDS. Alcohol Withdrawal: 10-20 mg PO/IV q4-6h initially, then taper. • Paediatric: Status Epilepticus / Febrile Seizure: 0.2-0.3 mg/kg IV slowly over 3-5 min OR 0.5 mg/kg rectally (max 10 mg <5 yr; 20 mg >=5 yr).
Administration & Meal Timing: See Administration & Counselling below. | Standard clinical schedule per indication.
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Renal: eGFR <30 mL/min: Active glucuronide and desmethyldiazepam metabolites accumulate; reduce dose and avoid repeated boluses. • Hepatic: Mild-moderate cirrhosis: Half-life doubles to quadruples; reduce dose by 50% (prefer Lorazepam). Severe hepatic failure: Contraindicated.
Renal: eGFR <30 mL/min: Active glucuronide and desmethyldiazepam metabolites accumulate; reduce dose and avoid repeated boluses. • Hepatic: Mild-moderate cirrhosis: Half-life doubles to quadruples; reduce dose by 50% (prefer Lorazepam). Severe hepatic failure: Contraindicated.
Renal: eGFR <30 mL/min: Active glucuronide and desmethyldiazepam metabolites accumulate; reduce dose and avoid repeated boluses. • Hepatic: Mild-moderate cirrhosis: Half-life doubles to quadruples; reduce dose by 50% (prefer Lorazepam). Severe hepatic failure: Contraindicated.
7. Contraindications, Precautions & High-Risk Warnings
- Contraindications: Severe respiratory insufficiency, myasthenia gravis, severe hepatic failure, untreated sleep apnoea, neonatal hyperbilirubinaemia (injectable benzyl alcohol/benzoate vehicle). • Precautions: High risk of accumulation and prolonged coma in elderly and cirrhotic patients; do not give IM (erratic painful absorption) or dilute in standard PVC infusion bags (adsorbs to plastic).
Key Clinical Precautions: Renal: eGFR <30 mL/min: Active glucuronide and desmethyldiazepam metabolites accumulate; reduce dose and avoid repeated boluses. • Hepatic: Mild-moderate cirrhosis: Half-life doubles to quadruples; reduce dose by 50% (prefer Lorazepam). Severe hepatic failure: Contraindicated.
8. Adverse Effects Profile
- Drowsiness, fatigue, ataxia, hangover sedation.
- Apnoea/hypotension (rapid IV), venous thrombophlebitis, severe withdrawal syndrome.
- Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Omeprazole / Fluconazole / Fluvoxamine (CYP2C19/3A4 inhibitors) -> markedly prolong diazepam sedation; Opioids / Alcohol -> fatal CNS/respiratory depression
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: Sedative effects persist into the next day due to long-acting breakdown products; avoid driving and alcohol; taper gradually under medical supervision.
- Meal & Clock Timing Instruction: See Administration & Counselling below. (Standard clinical schedule per indication.)
- Missed Dose Protocol: Take as soon as remembered unless close to next scheduled dose; never double the dose.
- Geriatric Dispensing Pearl: Schedule: Schedule H | NLEM 2022: Yes | Compendia: IP 2026 / NFI 7th Ed 2026 / NLEM 2022 / CDSCO Schedule H / BNF 90th Ed
Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Tablet: 2 mg, 5 mg, 10 mg; Injection: 5 mg/mL (2 mL ampoule = 10 mg); Rectal Solution/Suppository: 5 mg, 10 mg.
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 11 [11.15] (p. 147)
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [11.28] Lamotrigine & Topiramate — Broad-Spectrum Antiepileptics, Bipolar Mood Stabiliser & Migraine
- [11.8]-C131 Divalproex Sodium — Broad-Spectrum Antiepileptic & Mood Stabiliser (Enhances GABAergi
- [11.8]-C132 Valproic Acid — Broad-Spectrum Antiepileptic & Mood Stabiliser (Enhances GABAergi
- [11.10]-CMP133 Oxcarbazepine IP — Iminostilbene Voltage-Gated Sodium Channel Blocker (Antiepileptic
